Myricetin Increases Hepatic Peroxisome Proliferator-Activated Receptor α Protein Expression and Decreases Plasma Lipids and Adiposity in Rats

Table 2

Changes in the fat-pad weight in HFD-fed rats receiving 8-weeks treatment with myricetin or fenofibrate.

Variable (s)	RCD-fed	HFD-fed
	Vehicle	Vehicle	Myricetin (mg kg^−1 per day)			Fenofibrate
			75	150	300	(100 mg kg^−1 per day)
Epididymal WAT (mg 100 g BW^−1)	285.4 ± 12.7^d	396.8 ± 15.6^b	368.1 ± 16.1^a	338.5 ± 22.8^a, c	308.4 ± 19.2^a, c	293.9 ± 14.6^d
Perirenal WAT (mg 100 g BW)	162.5 ± 11.6^d	247.9 ± 12.1^b	228.6±13.5	198.9±13.9^a, c	185.3 ± 12.1^c	170.2 ± 11.7^d
Mesenteric WAT (mg 100 g BW)	122.1 ± 8.8^c	180.2 ± 11.5^a	171.5 ± 13.1^a	156.2 ± 10.3^a	136.9 ± 8.7^c	125.6 ± 9.2^c
Inguinal WAT (mg 100 g BW)	138.0 ± 10.3^c	210.2 ± 12.8^a	194.3 ± 11.8^a	170.6±11.0^a, c	151.1 ± 9.2^c	142.2 ± 10.5^c

Myricetin or fenofibrate was dissolved in distilled water for oral administration at the desired doses in a volume of 2 mL kg⁻¹ once a day into HFD-fed rats. The vehicle (distilled water) used to dissolve the tested medications was given at the same volume. All data represented as the mean ± SEM. ^a𝑃<.05 and ^b𝑃<.01 compared to the values of vehicle-treated RCD-fed rats in each group, respectively. ^c𝑃<.05 and ^d𝑃<.01 compared to the values of vehicle-treated HFD-fed rats in each group, respectively.